Smith+Nephew launches next-gen surgical robotics system

The Cori surgical system [Image courtesy of Smith+Nephew]

Competition continues to heat up in the robotic orthopedic surgery space, with Smith+Nephew (LON:SN) today announcing the launch of its next-gen Cori surgical system.

Cleared by FDA and available for both total and unicompartmental knee arthroplasty, the handheld Cori robotics platform is meant to be faster than S+N’s previous Navio system. On top of Cori, the British medtech giant is also launching its Real Intelligence suite of digital surgery solutions that are meant to improve patient engagement, pre-operative planning, digital and robotic surgery, post-operative assessment and outcomes measurement.

“The Real Intelligence brand is a statement of how Smith+Nephew thinks, innovates,and reimagines surgery,” said Skip Kiil, president of Orthopaedics for Smith+Nephew.

“The introduction of the Cori surgical system’…

Read more
  • 0

Titan Medical faces Nasdaq delisting

Titan Medical (TSX:TMD) announced today that the Nasdaq stock market has sent it a Staff Delisting Determination letter.

The robotic surgery system developer plans to appeal the determination by requesting a hearing by June 4.

Nasdaq, according to Titan Medical, claimed that the company had failed to comply with a rule that listed companies must have a minimum of $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations.

Titan Medical will continue to trade on the Toronto Stock Exchange.

Titan Medical lost nearly half its stock value in October 2019 after suspending the timeline for bringing its Sport robot-assisted surgery device to market due to lack of funds. CEO David McNally said in February that the company needed $85 million to finish developing its Sport robot-assisted surgery device and file for FDA clearance. The company said May 14 that it has raise…

Read more
  • 0